Notably, PD-L1 expression on tumor cells or immune cells, as well as tumor mutation burden (TMB), can predict the therapeutic benefit of ICIs, with ICIs being more efficacious in prolonging the survival of patients with higher PD-L1 expression or higher TMB [8, 9]. This evidence concerns the gene CD274 and neoplasm.